My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
Any palpable abnormality in a pregnant or postpartum womanpersisting for more than a few weeks needs a careful investigative workup to rule out PABC.
Although up to 90% of PABC presents as a palpable mass, there can be atypical presentations, including milk rejection from the affected breast or bloody nipple discharge.
Bloody nipple discharge can be especially difficult to differentiate from a benign or malignant origin as it may happen due to pregnancy-induced changes leading to delicate intraductal epithelial spurs that are easily traumatized and shed and thus not considered pathologic in all cases.
In the absence of clinically detectable masses or abnormality on cytology, these patients may be followed closely.
However, if bloody nipple discharge persists after several months postpartum, diagnostic studies should be performed to rule out pathology.
Patients with PABC are often found to have advanced disease at diagnosis, with the median size of tumor ranging from 3.4 to 4 cm and the reported incidence of axillary lymph node metastasis between 56% and 73%.
Delay in diagnosis is often due to the physiologic changes that occur in breasts during pregnancy that can pose challenges for differentiating a new mass from engorged and nodular breast tissue on a physical examination.
In the first and second trimesters, there is active proliferation and differentiation of the lobules, alveoli, and lactiferous ducts, leading to enlargement and increased overall density of breast tissue.
The prolactin level rises during the third trimester, which stimulates milk-producing cells to differentiate, and alveoli and milk ducts are filled with colostrum.
Around parturition, the breasts undergo lactogenesis, which leads to the secretion of colostrum and then milk.
PABC shares histology and some prognostic features with breast cancer occurring in other young women.
Invasive ductal carcinoma is the most common histologic subtype, followed by invasive lobular carcinoma.
The majority of tumors are grade II or III, and lymphovascular invasion is common.
However, the molecular subtypes of PABC seem to differ from those of non-PABC.
Several case-control studies have demonstrated that the hormone receptor status in PABC is more likely to be negative when compared with that in breast cancer in age-matched cohorts.
In contrast, there are conflicting reports of the HER-2 receptor status for PABC.
In a case-control study published in 1993 by Elledge and colleagues, 58% of the tumors from pregnant patients were positive for HER-2 on immunohistochemistry, whereas only 16% of age-matched non-pregnant patients had HER-2-positive tumors.
However, in a more contemporary report from the MD Anderson Cancer Center series of pregnant women by Middleton and colleagues, 28% of PABC cases had positive membrane staining for HER-2, and there was no significant difference when compared with breast carcinoma in young nonpregnant women.
Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during pregnancy or in the first postpartum year.
Breast cancer is the second most common malignancy affecting pregnant women.
It is estimated that one in 3,000 pregnant women is diagnosed with breast cancer and that up to 3% of all breast cancers are associated with pregnancy.
In general, breast cancer in young women is rare; the estimated incidence of breast cancer in women younger than 40 years of age was less than 4% in 2015 in the United States.
However, by definition, PABC occurs in women of reproductive age, and the average age of women with PABC is between 32 and 38 years of age.
The birth rate for women age 30 to 44 years has been steadily increasing in the past few decades, and as more women are delaying childbearing for various reasons, the incidence of PABC has risen and is expected to continue to rise.
As in non-PABC, the risk of PABC seems to be age related.
A large Canadian population cohort study using birth data from a national registry reported that PABC appeared to be more common among women with a first-term pregnancy occurring after the age of 35.
Peritoneal washing cytology (CY)+ in Pancreatic ductal adenocarcinoma (PDAC) is classified as M1 disease by the American Joint Committee on Cancer staging system and NCCN guidelines, whereas the Japanese General Rules for Pancreatic Cancer have not yet included the CY status for staging.
Hiroyoshi Tsuchida et al analysed well-maintained, nationwide database of 1970 patients with PDAC to evaluate the relationship among CY status, clinical factors, and overall survival and to clarify the clinical implications for operative resection in patients who are CY+ status.
It demonstrated that OS in patients who underwent resection was markedly worse in patients who were CY+ than in patients who were CY– who underwent resection and that peritoneal recurrence appeared earlier in patients who were CY+.
Incision of the mucosa in healthy tissue with appropriate safety margins (0.5 cm to 1.0 cm depending on whether or not the lesion is well defined):
The mucosa and submucosa are includedup to the intrinsic muscle fibers of the tongue
The deep resection margin should include:
A thin layer of the intrinsic muscles:Because of a possible invasion of the submucosa
Generally:
The wound is left to heal by secondary intention
Although the defect may be:Partially closedprimarilyOr covered with a skin graft
Indication:Precancerous, superficial suspicious lesions, limited to the epithelium of the tongue without previous biopsy:
The aim of surgery:
Is to remove all the lesion with adequate margins up to the healthy tissue with both diagnostic and curative intent
TYPE II GLOSSECTOMY (PARTIAI GLOSSECTOMY):Definition: It includes the lesion and adjacent normal mucosa, submucosa, and the intrinsic muscles up to the surface of the extrinsic muscles (when the directions of the muscle fibers change)
With appropriate safety margins (approximately 1.5 cm):The resection usually is diamond shaped on the surface, while more deeply, it is shaped like a truncated cone with the intrinsic muscles as the apex. The terminal branches of the lingual artery should be ligated
The lingual nerve is usually preserved
Closure may be partial or total with the objective of avoiding:Bleeding, postoperative edema, and retracted scars
Indication: Lesions infiltrating submucosa and superficially into intrinsic muscles, but not extrinsic muscles, or infiltration less than 10 mm deep
TYPE III GLOSSECTOMY:Type IIIa glossectomy (hemiglossectomy):Definition: The specimen includes the mucosa, submucosa, and intrinsic and extrinsic muscles ipsilateral to the lesion:The mucosa is resected up to healthy tissue with appropriate safety margins (at least 1.5 cm)
The lingual artery must be ligated and removed en bloc with the lingual and hypoglossal nerves, in the specimen of the primary tumor and neck nodes
The base of the ipsilateral tongue is preserved
The tip of the tongue can be preserved or not
Indication: Lesions infiltrating the intrinsic and minimally extrinsic muscles or infiltration greater than 10 mm but confined within the ipsilateral tongue
Type IIIb glossectomy (compartmental hemiglossectomy):Definition: The specimen includes the mucosa, submucosa, intrinsic and extrinsic muscles ipsilateral to the lesion, genioglossus, hyoglossus and styloglossus muscles, and the inferior portion of the palatoglossus muscle.
Medially:The midline raphe is included in the resection
The lingual nerve is resected as far cranially as possible
The hypoglossal nerve is removed after the ansa
The lingual artery and vein is ligated in proximity to the horn of the hyoid bone, and removed en bloc with specimen and neck nodes
Indication: Lesions massively infiltrating the intrinsic and extrinsic muscles but confined to the ipsilateral tongue
TYPE IV GLOSSECTOMY:Type IVa glossectomy (subtotal glossectomy):Definition: This is an anterior subtotal glossectomy
With preservation of both sides of the base of the tongue, posterior hyoglossus muscle, and hypoglossal and lingual nerves, from the less involved side.
Indication:Lesions that arise in the anterior portion of the mobile tongue and exceed the hemilingual area of origin involving the contralateral genioglossus muscle but limited to mobile tongue
Type IVb (near-total glossectomy):Definition: Type IVa glossectomy with extension to the ipsilateral base of the tongue:The following contralateral structures are preserved:Hyoglossus and styloglossus muscles, hypoglossal and lingual nerves, and lingual artery (functional unit of the base of the tongue)Indication: Massive lesions that exceed the border of the hemilingual area of origin infiltrating the ipsilateral base of the tongue and the contralateral genioglossus muscle
TYPE V GLOSSECTOMY (TOTAL GLOSSECTOMY):Definition: The specimen includes all of the mobile tongue and the base of the tongue transected at the level of the lingual arteries, hypoglossal, lingual nerves, and the floor of the mouth.Indication:Massive infiltrating lesions, for instance, those of the anterior ventral surface of the tongue, dorsum of the tongue, or the tongue base, which bilaterally involve the extrinsic genioglossus, hyoglossus, and styloglossus with impairment of the mobility of the tongue
What is Head and Neck Surgery?:
It is a surgical sub-specialty that deals mainly with benign and malignant tumors of the head and neck region, including:
The scalp, facial region, eyes, ears, nose, nasal fossae, paranasal sinuses, oral cavity, pharynx (nasopharynx, oropharynx, hypopharynx), larynx (supraglotic larynx, glottis larynx, subglotic larynx), thyroid gland, parathyroid gland, salivary glands (parotid glands, submandibular glands, sublingual glands, minor salivary glands), soft tissues of the neck, skin of the head and neck region.
The head and neck surgeon’s work area:Does not cover tumors or diseases of the brain and other areas of the central nervous system or those of the cervical spine:This is the neurosurgeon field.
Among the diagnostic procedures performed by the head and neck surgeon, are the following:
Nasopharyngolaryngoscopy:
Performed to examine, evaluate and, possibly perform a biopsy, of oral cavity, pharyngeal and laryngeal lesions.
The surgeries most commonly performed by the head and neck surgeon are:
Total or near total thyroidectomies
Hemithryoidectomies (lobectomies)
Comprehensive neck dissections
Selective neck dissections
Maxillectomies:
Total maxillectomy
Subtotal maxillectomy
Infrastructure maxillectomy
Suprastructure maxillectomy
Medial maxillectomy
Mandibulectomy:
Segmental
Marginal
Tracheostomy
Salivary gland surgeries:
Parotid gland operations:
Limited superficial parotidectomy with identification and preservation of the facial nerve
Superficial parotidectomy with identification and preservation of the facial nerve
Near total parotidectomy with identification and preservation of the facial nerve
Total parotidectomy
Submandibular gland resection
Sublingual gland resection
Resection of tumors of the oral cavity:
Glossectomy
Resection of the floor of the mouth tumors
Resection of tumors of the pharynx
Resection of tumors of the larynx
Split-thickness skin grafts
Full-thickness skin grafts
Sentinel lymph node mapping and sentinel lymph node biopsy
Resection of malignant skin tumors (BCC, SCC, melanoma) of the head and neck region
The formation of the head and neck surgeon includes mastering the following subjects:
Surgical Anatomy
History and Basic Principles of Head and Neck Surgery
Epidemiology, Etiology, and Pathology of Head and Neck Diseases
Diagnostic Radiology of the Head and Neck Region
Tumors of the Scalp, Skin and Melanoma
Eyelids and Orbit
Nasal Cavity and Paranasal Sinuses
Skull Base and Temporal Bone
Lips and Oral Cavity
Pharynx and Esophagus
Larynx and Trachea
Cervical Lymph Nodes
Thyroid and Parathyroid Glands
Salivary Glands
Neurogenic Tumors and Paragangliomas
Soft Tissue Tumors
Bone Tumors and Odontogenic Lesions
Reconstructive Surgery
Oncologic Dentistry and Maxillofacial Prosthetics
Principles of Radiation Oncology
Principles of Chemotherapy
Molecular Oncology, Genomics and Immunology
Nutrition
Biostatistic
Rodrigo Arrangoiz MS, MD, FACS a head and neck surgeon / endocrine surgeon / surgical oncologist and is a member of Center for Advanced Surgical Oncology at Palmetto General Hospital:
Training:
• General surgery:
• Michigan State University:
• 2004 al 2010
• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:
• Fox Chase Cancer Center (Filadelfia):
• 2010 al 2012
• Masters in Science (Clinical research for health professionals):
• Drexel University (Filadelfia):
• 2010 al 2012
• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:
• IFHNOS / Memorial Sloan Kettering Cancer Center:
👉The most recent publication of our CovidSurg collaboration showed head and neck surgery during the pandemic, represents a significant risk of contagion of # COVID19, which is significantly higher (an order of magnitude) than the risk of community transmission.
👉The study can be seen in the Cancer journal of the American Cancer Society
An extreme form of parathyroid bone disease termed osteitis fibrosa cystica is characterized by significant loss of bone density, development of bone cysts and brown tumors (shown below), skeletal deformity, bone pain, and a propensity for pathologic fractures. Fortunately, it is quite rarely seen these days.